{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:27:47Z","timestamp":1790645267158,"version":"4.1.0"},"reference-count":82,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal hematopoietic disorders that pose unique challenges in women, particularly regarding thrombosis, bleeding, fertility, and pregnancy. Women with MPN exhibit distinct thrombotic and sometimes contradictory bleeding profiles, including a higher prevalence of unusual thrombosis such as cerebral and splanchnic vein thrombosis and increased risk of hemorrhage from anti-thrombotic medication, acquired von Willebrand syndrome and platelet dysfunction. Estrogen-containing contraceptives should generally be avoided due to thrombotic risk. Around 10\u201320% of newly diagnosed MPN cases are women of childbearing age and the number is increasing annually. MPN patients when compared to controls have a lower rate of live birth rate of 71% vs. 80% with a hazard ratio of 0.78 (95% CI: 0.68\u20130.90), and increased preterm birth (14% vs. 4%), low birth weight (&lt;2500 g, 10% vs. 4%), and increased cesarean section rate (32% vs. 17%). Management of MPN-related pregnancy requires specific considerations regarding the prevention of thrombosis, bleeding, and pregnancy-related complications. Management strategies during pregnancy include low-dose aspirin and consideration of low-molecular-weight heparin and interferon. Despite these challenges, most women with MPN can achieve successful pregnancies with optimized care. In this case-based review, we present two cases that illustrate key aspects of managing MPN in women, summarize the current literature, and propose a diagnostic and management framework tailored to these complexities.<\/jats:p>","DOI":"10.3390\/jcm14051537","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:13:18Z","timestamp":1740463998000},"page":"1537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-1751","authenticated-orcid":false,"given":"Thita","family":"Chiasakul","sequence":"first","affiliation":[{"name":"Center of Excellence in Translational Hematology, Division of Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-6788","authenticated-orcid":false,"given":"Ross I.","family":"Baker","sequence":"additional","affiliation":[{"name":"Western Australia Centre for Thrombosis and Haemostasis, Health Futures Institute, Murdoch University, Perth, WA 6150, Australia"},{"name":"Clinical Research Unit, Perth Blood Institute, Perth, WA 6005, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E451","DOI":"10.1002\/ajh.26362","article-title":"Cause-Specific Mortality Following Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the US Population, 2001\u20132017","volume":"96","author":"Dores","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., and Ruchutrakool, T. (2019). A Systematic Review and Meta-Analysis of the Prevalence of Thrombosis and Bleeding at Diagnosis of Philadelphia-Negative Myeloproliferative Neoplasms. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5387-9"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential Thrombocythemia: 2024 Update on Diagnosis, Risk Stratification, and Management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and Treatment of Polycythemia Vera: A Review","volume":"333","author":"Tremblay","year":"2024","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.2023020729","article-title":"How I Treat Myeloproliferative Neoplasms in Pregnancy","volume":"143","author":"Robinson","year":"2024","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2634853520978210","DOI":"10.1177\/2634853520978210","article-title":"The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep","volume":"13","author":"Accurso","year":"2020","journal-title":"Clin. Med. Insights Blood Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","article-title":"Diagnosis, Prevention, and Management of Bleeding Episodes in Philadelphia-Negative Myeloproliferative Neoplasms: Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)","volume":"95","author":"Appelmann","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/hematology.2019001318","article-title":"From Budd-Chiari Syndrome to Acquired von Willebrand Syndrome: Thrombosis and Bleeding Complications in the Myeloproliferative Neoplasms","volume":"2019","author":"Stein","year":"2019","journal-title":"Hematology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex Determines the Presentation and Outcomes in MPN and Is Related to Sex-Specific Differences in the Mutational Burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between Gender, Disease Features and Symptom Burden in Patients with Myeloproliferative Neoplasms: An Analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer","year":"2017","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex Differences in the JAK2 V617F Allele Burden in Chronic Myeloproliferative Disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two Clinical Phenotypes in Polycythemia Vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"874146","DOI":"10.1155\/2011\/874146","article-title":"Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms","volume":"2011","author":"Stein","year":"2011","journal-title":"Thrombosis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jth.12967","article-title":"Qualitative and Quantitative Modifications of von Willebrand Factor in Patients with Essential Thrombocythemia and Controlled Platelet Count","volume":"13","author":"Lancellotti","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"360.e1","DOI":"10.1016\/j.ajog.2023.09.012","article-title":"The Risk of Venous Thromboembolism in Oral Contraceptive Users: The Role of Genetic Factors\u2014A Prospective Cohort Study of 240,000 Women in the UK Biobank","volume":"230","author":"Faro","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hoc.2020.11.005","article-title":"Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms","volume":"35","author":"Shallis","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of Myeloproliferative Neoplasms\u2014Trends by Subgroup and Age in a Population-Based Study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_20","first-page":"553","article-title":"Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature","volume":"121","author":"Nicol","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and Risk Factors for Bleeding in 1104 Patients with Essential Thrombocythemia or Prefibrotic Myelofibrosis Diagnosed According to the 2008 WHO Criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and Prognosis among 1545 Patients with Contemporary Polycythemia Vera: An International Study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41375-022-01688-w","article-title":"Pregnancy and Childbirth Outcomes in Women with Myeloproliferative Neoplasms-a Nationwide Population-Based Study of 342 Pregnancies in Sweden","volume":"36","author":"Landtblom","year":"2022","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/bloodadvances.2024013777","article-title":"Risk of Bleeding in Patients with Essential Thrombocythemia and Extreme Thrombocytosis","volume":"8","author":"Venkat","year":"2024","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jth.15311","article-title":"\u201cThey Don\u2019t Really Take My Bleeds Seriously\u201d: Barriers to Care for Women with Inherited Bleeding Disorders","volume":"19","author":"Arya","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of Blood Counts with Vascular Complications in Essential Thrombocythemia: Analysis of the Prospective PT1 Cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","article-title":"Thromboses and Hemorrhages Are Common in MPN Patients with High JAK2V617F Allele Burden","volume":"96","author":"Bertozzi","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F Mutational Status and Allele Burden May Be Related with the Risk of Venous Thromboembolic Events in Patients with Philadelphia-Negative Myeloproliferative Neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12185-015-1871-4","article-title":"Bleeding Complications in BCR-ABL Negative Myeloproliferative Neoplasms: Prevalence, Type, and Risk Factors in a Single-Center Cohort","volume":"102","author":"Kander","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-023-05578-8","article-title":"Correlation between IPSET-t Risk at Diagnosis and Subsequent Hemorrhage in Patients with Essential Thrombocythemia; a Single Institution Experience","volume":"103","author":"Tosoni","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12185-023-03650-7","article-title":"Prediction of Major Bleeding Events in 1381 Patients with Essential Thrombocythemia","volume":"118","author":"Stuckey","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3324\/haematol.2022.281388","article-title":"Aspirin in Essential Thrombocythemia. For Whom? What Formulation? What Regimen?","volume":"108","author":"Cattaneo","year":"2023","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0609.1988.tb00835.x","article-title":"Platelet Function in Myeloproliferative Disorders: Characterization and Sequential Studies Show Multiple Platelet Abnormalities, and Change with Time","volume":"40","author":"Baker","year":"1988","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.20452\/pamw.3211","article-title":"Prevalence of Acquired von Willebrand Syndrome during Essential Thrombocythemia: A Retrospective Analysis of 170 Consecutive Patients","volume":"125","author":"Mital","year":"2015","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","article-title":"Factors Related to the Development of Acquired von Willebrand Syndrome in Patients with Essential Thrombocythemia and Polycythemia Vera","volume":"41","author":"Rottenstreich","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/jth.15717","article-title":"Increased Cleavage of von Willebrand Factor by ADAMTS13 May Contribute Strongly to Acquired von Willebrand Syndrome Development in Patients with Essential Thrombocythemia","volume":"20","author":"Kubo","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5045\/br.2023.2022218","article-title":"Acquired von Willebrand Syndrome in Patients with Philadelphia-Negative Myeloproliferative Neoplasm","volume":"58","author":"Song","year":"2023","journal-title":"Blood Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and Haemorrhage in Polycythaemia Vera and Essential Thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand Disease in Patients with High Platelet Counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.21730","article-title":"Polycythemia Vera-associated Acquired von Willebrand Syndrome despite Near-normal Platelet Count","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.08.002","article-title":"Evaluation of Different Diagnostic Tools for Detection of Acquired von Willebrand Syndrome in Patients with Polycythemia Vera or Essential Thrombocythemia","volume":"218","author":"Janjetovic","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_42","unstructured":"Scharf, R.E. (2017). Platelets in Thrombotic and Non-Thrombotic Disorders, Pathophysiology, Pharmacology and Therapeutics: An Update, Springer."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09537104.2019.1584668","article-title":"Evaluation of Platelet Function in Essential Thrombocythemia under Different Analytical Conditions","volume":"31","author":"Lussana","year":"2020","journal-title":"Platelets"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Repsold, L., and Joubert, A.M. (2021). Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders. Cells, 10.","DOI":"10.3390\/cells10113034"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/ATVBAHA.121.316373","article-title":"Platelet Heterogeneity in Myeloproliferative Neoplasms","volume":"41","author":"Thomas","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2141.1995.tb08901.x","article-title":"Rapid Detection of Hereditary and Acquired Platelet Storage Pool Deficiency by Flow Cytometry","volume":"89","author":"Gordon","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kelliher, S., Gamba, S., Weiss, L., Shen, Z., Marchetti, M., Schieppati, F., Scaife, C., Madden, S., Bennett, K., and Fortune, A. (2023). Platelet Proteo-Transcriptomic Profiling Validates Mediators of Thrombosis and Proteostasis in Patients with Myeloproliferative Neoplasms. bioRxiv.","DOI":"10.1101\/2023.10.23.563619"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1999.01399.x","article-title":"Thrombosis and Bleeding in Myeloproliferative Disorders: Identification of At-risk Patients with Whole Blood Platelet Aggregation Studies","volume":"105","author":"Manoharan","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cyto.b.21642","article-title":"Platelet Characteristics in Patients with Essential Thrombocytosis","volume":"94","author":"Pedersen","year":"2018","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ross, D.M., Liang, H.P.H., Iqra, Z., Whittaker, S., Tan, C.W., Dale, B.J., and Chen, V.M. (2023). Platelets from Patients with Myeloproliferative Neoplasms Have Increased Numbers of Mitochondria That Are Hypersensitive to Depolarization by Thrombin. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36266-2"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100425","DOI":"10.1016\/j.xcrm.2021.100425","article-title":"Platelet Transcriptome Identifies Progressive Markers and Potential Therapeutic Targets in Chronic Myeloproliferative Neoplasms","volume":"2","author":"Shen","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10760296221117482","DOI":"10.1177\/10760296221117482","article-title":"Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis","volume":"28","author":"Manoharan","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.1002\/ajh.26739","article-title":"Perioperative Management of Myeloproliferative Neoplasms: A Pan-Canadian Physician Survey and International Expert Opinion","volume":"97","author":"Szuber","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2023-188259","article-title":"Perioperative Outcomes and Management in Patients with Myeloproliferative Neoplasms: A Multicentric Retrospective Analysis of 354 Surgical Interventions","volume":"142","author":"Szuber","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms: A Population-Based Cohort Study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and Cause of Death in Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.3390\/cimb46080496","article-title":"Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications\u2014A Narrative Review","volume":"46","author":"Todor","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased Adhesion to Endothelial Cells of Erythrocytes from Patients with Polycythemia Vera Is Mediated by Laminin A5 Chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","article-title":"Gender Effect on Phenotype and Genotype in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: Results from the MYSEC Project","volume":"8","author":"Barraco","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11739-011-0634-3","article-title":"Polycythemia Vera: Gender-Related Phenotypic Differences","volume":"7","author":"Landolfi","year":"2012","journal-title":"Intern. Emerg. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms in a Single Center Experience","volume":"104","author":"Tremblay","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct Clinical, Laboratory and Molecular Features of Myeloproliferative Neoplasm Patients with Splanchnic Vein Thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic Vein Thromboses Associated with Myeloproliferative Neoplasms: An International, Retrospective Study on 518 Cases","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative Neoplasms in Budd-Chiari Syndrome and Portal Vein Thrombosis: A Meta-Analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtha.2024.10.012","article-title":"Splanchnic Vein Thrombosis: Management for the Thrombosis Specialist","volume":"23","author":"Barnum","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/j.jtha.2024.06.029","article-title":"Anticoagulation for Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis","volume":"22","author":"Chrysafi","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the Treatment of Noncirrhotic Splanchnic Vein Thrombosis: An Interventional Prospective Cohort Study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ramanathan, G., Hoover, B.M., and Fleischman, A.G. (2020). Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN. Cancers, 12.","DOI":"10.3390\/cancers12082038"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/cncr.21891","article-title":"Estrogen-Based Hormone Therapy and Thrombosis Risk in Women with Essential Thrombocythemia","volume":"106","author":"Gangat","year":"2006","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy Outcomes in Myeloproliferative Neoplasms: UK Prospective Cohort Study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41375-024-02216-8","article-title":"Childbirth Rates in Women with Myeloproliferative Neoplasms","volume":"38","author":"Landtblom","year":"2024","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of Treatments for Myeloproliferative Neoplasms During Pregnancy with Birth Rates and Maternal Outcomes: A Systematic Review and Meta-Analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_74","first-page":"1","article-title":"Estimated Pregnancy Rates and Rates of Pregnancy Outcomes for the United States, 1990\u20132008","volume":"60","author":"Ventura","year":"2012","journal-title":"Natl. Vital. Stat. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e882","DOI":"10.1097\/HS9.0000000000000882","article-title":"Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET","volume":"7","author":"Wille","year":"2023","journal-title":"HemaSphere"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/ajh.27416","article-title":"Aspirin Therapy Is Associated with a Lower Risk of Pregnancy Loss in Both JAK2- and CALR-Mutated Essential Thrombocythemia\u2014A Mayo Clinic Study of 200 Pregnancies","volume":"99","author":"Gangat","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy Outcomes, Risk Factors, and Cell Count Trends in Pregnant Women with Essential Thrombocythemia","volume":"98","author":"How","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact of Mutational Status on Pregnancy Outcome in Patients with Essential Thrombocytemia","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased Risk of Pregnancy Complications in Patients with Essential Thrombocythemia Carrying the JAK2 (617V>F) Mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated Interferon Alpha-2a for Essential Thrombocythemia during Pregnancy: Outcome and Safety. A Case Series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0140-6736(23)00693-1","article-title":"Heparin for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An International Open-Label, Randomised Controlled Trial","volume":"402","author":"Quenby","year":"2023","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:06Z","timestamp":1760028126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051537"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051537","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}